|
The National Pharmaceutical Pricing Authority (NPPA) has fixed retail price of 40 new drugs including generic fixed dose formulations of diabetes drugs dapagliflozin and sitagliptin, among others.
The Authority discussed retail price fixation of 42 new drugs and approved 40 of them, except for two formulations on which the marketers made representation on the retail price recommended by the Multidisciplinary Committee of Experts.
The products, for which the retail prices were fixed include dapagliflozin and metformin hydrochloride (extended release) tablets marketed by Macleods Pharmaceuticals, Glenmark Pharmaceuticals and Abbott Healthcare.
Retail price for sitagliptin and metformin hydrochloride (as extended release) tablets marketed by MSN Laboratories, Sun Pharma Laboratories, Macleods Pharmaceuticals, and Wockhardt Ltd were also fixed during the meeting.
Out of the 42 formulations, pantaprazole powder for oral suspension (sodium bicarbonate as buffer) from Alkem Laboratories and lidocaine patch 5 per cent from Hetero Healthcare were not fixed by the Authority during the meeting.
Alkem Laboratories and Hetero Healthcare made representations to the Authority on the retail price recommended by the Multidisciplinary Committee of Experts (MDC) in its last meeting held on September 13, 2022, and the Authority deliberated upon the matter in detail and decided to refer the matter to the MDC for examination of the representation.
The Authority meeting held on September 27, also fixed the retail price of dextrose injection 25% w/v in 100 ml in specific container, mannitol injection 20 gm per 100 ml in 100 ml pack in special package, Metronidazole Injection IP 500 mg/100 ml in 100 ml pack with special packaging and from Axa Parenterals.
It has also extended the ceiling price of sodium chloride injection 0.9% in 500 ml with special feature packaging, glucose injections 5% in 500 ml non glass with special features with euro head, and ringer lactate injection in special packaging among others for Puerto Life Sciences Pvt Ltd, dextrose injection 5% in 500 ml pack with packaging in non glass with special features with brand ‘Safe Port’ from Sachin Parenteral, among others, during the meeting.
|